Indeed, of the over 1600 clinical trials on oncology interventions against pathways related to tumor vasculature reported worldwide since January 2010 (Table S1), 233 are related to VEGF, either novel targeting agents or post-anti-VEGF therapy (Table S2). This evidence concerns the gene VEGFA and neoplasm.